TSE EURL
Istituto Zooprofilattico Sperimentale del
Piemonte, Liguria e Valle d'Aosta – Torino

Istituto Superiore di Sanità – Roma

Proficiency testing for veterinary laboratories

Histopathology and immunohistochemistry interpretation

Distribution date: Dicember 2019/January 2020

General comments

The TSE interpretation EQA is an exercise that allows all the NRLs to demonstrate their competence at reading stained/immunolabelled slides as part of their TSE diagnostic capability.

Attached below you will find a table summarising the results of the 2019 EQA round in conjunction with each participant ID.

The use of inconclusive/unsuitable for a case in which a definitive diagnosis is considered possible is not an 'incorrect result in this context. A negative case called positive, or a positive case interpreted as negative are the only results which are considered 'incorrect'. However, for any HE slide which is considered inconclusive or unsuitable, the IHC result is also taken into consideration. If a definitive positive or negative result is given which concurs with the IHC this is also considered a 'safe' outcome.

Correct and 'Safe' results are highlighted green. 'Incorrect' results are highlighted in red. Inconclusive or unsuitable returns are highlighted in yellow.

In the scrapie IHC category, readers were also invited to comment on whether the case is classical or atypical. Where a case is correctly diagnosed as positive, but subsequently misclassified or not classified, this has been identified on the table by highlighting the fonts of either "Pos-A" or "Pos-C" in pink.

You should each have received email notification of your unique 'ObserverID'. You will need this to identify your results in the table. Please keep this information safely – your ID will NOT change with subsequent rounds. If you have misplaced your ID then please contact Dr Giuseppe Ru (**giuseppe.ru@izsto.it**) directly, and the information will be re-sent. If you know of new staff who require to be added to the programme, or existing members of staff who no longer need to participate in this EQA then please contact us.

It is important to review any cases for which you have given an incorrect answer (highlighted in <u>red</u> or <u>pink</u>) and fill the 'Slide review form' (at the end of this document) and return it to Giuseppe Ru (giuseppe.ru@izsto.it) and a copy to Cristina Casalone (cristina.casalone@izsto.it) and Barbara Iulini (barbara.iulini@izsto.it).
**<u>Please use one form for each misclassified case.</u>**

This confirms for the EURL (and your own third party quality systems) that appropriate follow-on review of sections has taken place with those readers who require to re-read particular slides.

Comments on the results

The summary table below has grouped the cases according to species so if you wish to refer back to a particular case, please check the case number carefully at the top of the table.

Thank you.

Date:

Cristina Casalone..
Referent for Confirmatory tests, Histopathology and immunohistochemistry within the TSE EURL at IZSPLVA

Barbara Iulini...
Veterinary pathologist of Neuropathology Laboratory at IZSPLVA Italy

Giuseppe Ru..
Director of TSE EURL

Case number	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15
Test Type	H&E	H&E	IHC	IHC	IHC	IHC	IHC	IHC	IHC	IHC	IHC	IHC	IHC	H&E	IHC
Gold standard result	Pos	Pos	Neg	Pos-C	Neg	Pos-A	Pos	Pos-C	Neg	Pos-C	Pos-C	Pos-C	Pos-A	Neg	Neg
Species	Bov	Ov	Ov	Ov	Ov	Ov	Bov	Ov	Ov	Ov	Ov	Ov	Ov	Bov	Bov
Result of all H&E sections															
User ID															
078	Pos	Pos	Neg	Pos-C	Neg	Inc	Pos	Pos-C	Neg	Pos-C	Pos-C	Pos-C	Pos-A	Neg	Neg
168	Pos	Pos	Neg	Pos-C	Neg	Pos-A	Pos	Pos-C	Neg	Pos-C	Pos-C	Pos-C	Pos-A	Neg	Neg
172	Pos	Pos	Neg	Pos-C	Neg	Pos-C	Pos	Pos-C	Neg	Pos-C	Pos-C	Pos-A	Pos-A	Neg	Neg
184	Pos	Pos	Neg	Pos-C	Neg	Pos-A	Pos	Pos-C	Neg	Pos-C	Pos-C	Pos-C	Pos-A	Uns	Neg
227	Inc	Pos	Neg	Pos-C	Neg	Inc	Pos	Inc	Neg	Pos-C	Pos-A	Pos-A	Pos-A	Uns	Neg
232	Pos	Pos	Neg	Pos-C	Neg	Pos-C	Pos	Pos-C	Neg	Pos-A	Pos-A	Pos-A	Pos-A	Uns	Neg
261	Pos	Pos	Neg	Pos-C	Neg	Pos-A	Pos	Pos-C	Neg	Pos-C	Pos-C	Pos-C	Pos-A	Neg	Neg
288	Pos	Pos	Neg	Pos-C	Neg	Pos-A	Pos	Pos-C	Neg	Pos-C	Pos-C	Pos-C	Pos-A	Uns	Neg
307	Pos	Pos	Neg	Pos-C	Inc	Inc	Pos	Pos-A	Neg	Pos-C	Pos-C	Pos-A	Pos-A	Inc	Neg
346	Pos	Inc	Neg	Pos-C	Neg	Pos-A	Pos	Pos-C	Neg	Pos-C	Pos-C	Pos-C	Pos-C	Uns	Inc
393	Pos	Pos	Neg	Pos-C	Neg	Inc	Pos	Pos-C	Neg	Pos-C	Pos-C	Pos-C	Pos-A	Uns	Neg
403	Pos	Pos	Neg	Pos-C	Neg	Pos-A	Pos	Pos-C	Neg	Pos-C	Pos-C	Pos-C	Pos-A	Inc	Neg
423	Pos	Pos	Neg	Pos-C	Neg	Inc	Pos	Pos-C	Neg	Pos-C	Pos-C	Pos-C	Pos-A	Neg	Neg
494	Pos	Pos	Neg	Pos-C	Neg	Inc	Pos	Pos-C	Uns	Pos-C	Pos-C	Pos-C	Inc	Uns	Inc
530	Inc	Pos	Neg	Pos-C	Neg	Pos-A	Pos	Pos-C	Neg	Pos-C	Pos-C	Pos-C	Pos-A	Uns	Neg
546	Pos	Pos	Inc	Pos-C	Neg	Inc	Pos	Pos-C	Uns	Pos-C	Pos-C	Pos-C	Pos-A	Uns	Neg
627	Pos	Pos	Neg	Pos-C	Neg	Pos-A	Pos	Pos-C	Neg	Pos-C	Pos-C	Pos-C	Pos-A	Neg	Neg
663	Pos	Pos	Neg	Pos-C	Neg	Inc	Pos	Pos-C	Uns	Pos-C	Pos-C	Pos-C	Pos-A	Uns	Neg
668	Pos	Pos	Neg	Pos-C	Neg	Inc	Pos	Pos-C	Neg	Pos-C	Pos-C	Pos-A	Pos-A	Neg	Neg
683	Pos	Pos	Neg	Pos-C	Neg	Inc	Pos	Pos-A	Neg	Pos-C	Pos-C	Pos-A	Pos-A	Inc	Neg
685	Inc	Pos	Neg	Pos-C	Inc	Pos-A	Pos	Pos-C	Neg	Pos-C	Pos-C	Pos-C	Pos-C	Uns	Neg
710	Pos	Inc	Neg	Pos-C	Neg	Inc	Pos	Pos-C	Neg	Pos-C	Inc	Pos-C	Inc	Neg	Neg
726	Pos	Pos	Neg	Pos-C	Neg	Pos-C	Pos	Pos-C	Inc	Pos-C	Pos-C	Pos-C	Pos-A	Neg	Neg
729	Inc	Pos	Inc	Pos-C	Inc	Inc	Pos	Pos-C	Neg	Pos-C	Pos-C	Pos-C	Pos-A	Uns	Inc
743	No ans	No ans	Neg	Pos-C	Neg	Pos-A	Pos	Pos-C	Neg	Pos-C	Pos-C	Pos-A	Pos-A	Neg	Pos
786	Pos	Pos	Neg	Pos-C	Neg	Pos-A	Pos	Pos-C	Neg	Pos-C	Pos-C	Pos-C	Pos-A	Neg	Neg
808	Pos	Pos	Inc	Pos-C	Inc	Pos-A	Pos	Pos-C	Neg	Pos-C	Pos-C	Pos-C	Pos-C	Neg	Neg
822	Inc	Pos	Neg	Pos-C	Neg	Pos-C	Pos	Pos-C	Neg	Pos-C	Pos-C	Inc	Pos-A	Uns	Neg
912	Pos	Pos	Neg	Pos-C	Neg	Uns	Pos	Pos-C	Neg	Pos-C	Pos-C	Pos-C	Pos-A	Neg	Neg
924	Inc	Pos	Neg	Pos-C	Neg	Inc	Pos	Pos-C	Neg	Pos-C	Pos-C	Pos-C	Pos-A	Neg	Inc
962	Uns	Pos	Neg	Pos-C	Neg	Pos-A	Pos	Pos-C	Neg	Pos-C	Pos-C	Pos-C	Pos-A	Uns	Neg

Histopathology and immunohistochemistry interpretation
Dicember 2019/January 2020

Slide review form

Observer ID:	
Date of EQA round:	
Case number:	
Original observer result:	
Intended (gold standard) result:	
Date of review:	
Further observer comments following review:	